Afrezza (insulin human) Inhalation Powder + insulin degludec
ApprovedCompleted 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type 1 Diabetes
Conditions
Type 1 Diabetes
Trial Timeline
Mar 31, 2022 → Oct 17, 2022
NCT ID
NCT05243628About Afrezza (insulin human) Inhalation Powder + insulin degludec
Afrezza (insulin human) Inhalation Powder + insulin degludec is a approved stage product being developed by MannKind Corp for Type 1 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT05243628. Target conditions include Type 1 Diabetes.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05243628 | Approved | Completed |
Competing Products
20 competing products in Type 1 Diabetes
Other Products from MannKind Corp
Afrezza plus One Drop | PremiumApproved
80
Technosphere insulinApproved
80
Afrezza + insulin degludec + Rapid-acting Insulin Analog + Basal InsulinApproved
80
Technosphere® Insulin with MedTone C Inhaler + Technosphere ®Insulin with Gen2 Inhaler + Insulin Aspart in combination with a basal insulinPhase 3
72
Technosphere® Insulin + Technosphere PowderPhase 3
72